Skip to main content
Caplight Logo









Enterprise Therapeutics

Enterprise Therapeutics

Private
BrightonHealthcare & Life Scienceshttps://enterprisetherapeutics.com/

Last Round

Series B

Extension

Jan 30, 2024

Total Funding Raised

$87.1M

Company Overview

Enterprise Therapeutics is a biopharmaceutical company that discovers and develops novel therapies for the treatment of respiratory diseases such as cystic fibrosis, COPD, and severe asthma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cystic fibrosisepithelial sodium channel blockerENaC blockermucus clearancerespiratory diseasesmall molecule therapeuticsdrug discoveryinhaled therapybiotechclinical stagebiopharmatherapeutic assetdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enterprise Therapeutics Comparables

Compare Enterprise Therapeutics with similar companies based on industry and business-model similarity.

Enterprise Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kither Biotech
89%
Parion Sciences
87%
Aer Therapeutics
81%

Enterprise Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 30, 2024
M&AOct 7, 2020
GrantOct 15, 2019
Series BApr 12, 2018
GrantApr 5, 2017
VC Round
Nov 10, 2016

Key People

Founding team and executive leadership

Martin Gosling

Chief Scientific Officer, Co-founder

Founding Team

John Ford

CEO

Executive Team

Enterprise Therapeutics Investors

Notable investors and investment history

Enterprise Therapeutics investors
InvestorRounds
ForbionSeries B Extension, Series B
IP GroupSeries B Extension, Series B
Epidarex CapitalSeries B Extension, Series B, Series A, VC Round
Cystic Fibrosis TrustGrant
Versant VenturesSeries B Extension, Series B
Imperial InnovationsSeries A, VC Round
Panakès PartnersSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Monthly visitors increased 37% MoM, reaching 1.2K.

  • Jan 30, 2024

    $33M round led by Panakès Partners.

Enterprise Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enterprise Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enterprise Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrighton
Employee Range12
Year Founded2014
Last FundingJan 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?